Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial Theodore F. LoganFayega JadaliCandace Johnson Original Article Pages: 433 - 444
Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat Jing LiuEric H. KrautKenneth K. Chan Original Article Pages: 445 - 453
Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver Shogo OzawaMasashi HamadaYasuo Ohno Original Article Pages: 454 - 458
The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer Jean-Marc FerreroEmmanuel ChamoreyGérard Milano Original Article Pages: 459 - 464
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol James P. ThomasKendra D. TutschGeorge Wilding Original Article Pages: 465 - 472
Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518 Mirjam CrulLaurens V. BeerepootJan H. Schellens Original Article Pages: 473 - 478
In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines Ioannis A. AvramisGaryfallia ChristodoulopoulosVassilios I. Avramis Original Article Pages: 479 - 489
Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts Henriette GourdeauPhilippe GenneGiorgio Attardo Original Article Pages: 490 - 496
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia Jorge CortesApostolia M. TsimberidouFrancis J. Giles Original Article Pages: 497 - 500
Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice Maria V. PapadopoulouMing JiMelinda G. Hollingshead Original Article Pages: 501 - 508
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925 Patricia E. SchroederBrian B. Hasinoff Original Article Pages: 509 - 513
Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule Nadja E. SchoemakerRon A. MathôtJos H. Beijnen Short Communication Pages: 514 - 517